Curapath and Cristal Therapeutics Sign Co-Exclusive License of CliCrยฎ Bioconjugation Platform
Curapath and Cristal Therapeutics partner to bring CliCrยฎ bioconjugation to targeted nanoparticle delivery, advancing next-generation therapies.
PATERNA, VALENCIA, SPAIN, November 26, 2025 /EINPresswire.com/ -- ๐๐๐ฟ๐ฎ๐ฝ๐ฎ๐๐ต,, a leading innovator in the development and manufacturing of polymer and lipid-based drug delivery systems, and Cristal ๐๐ฟ๐ถ๐๐๐ฎ๐น ๐ง๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ฒ๐๐๐ถ๐ฐ๐, a biotech company developing innovative conjugation technologies, today announced they entered into a co-exclusive license agreement for the ๐๐น๐ถ๐๐ฟยฎ ๐ฏ๐ถ๐ผ๐ฐ๐ผ๐ป๐ท๐๐ด๐ฎ๐๐ถ๐ผ๐ป ๐ฝ๐น๐ฎ๐๐ณ๐ผ๐ฟ๐บ. The platform offers a powerful and scalable solution for efficient, site-specific and stable conjugation of biomolecules, addressing a critical challenge in ๐ฎ๐ฐ๐๐ถ๐๐ฒ ๐๐ฎ๐ฟ๐ด๐ฒ๐๐ถ๐ป๐ด and targeted drug delivery to extrahepatic tissues.Under the agreement, Curapath will be ๐๐ต๐ฒ ๐ฒ๐ ๐ฐ๐น๐๐๐ถ๐๐ฒ ๐ฐ๐ผ๐ป๐๐ฟ๐ฎ๐ฐ๐ ๐บ๐ฎ๐ป๐๐ณ๐ฎ๐ฐ๐๐๐ฟ๐ฒ๐ฟ (๐๐๐ ๐ข) ๐๐ผ ๐ฎ๐ฝ๐ฝ๐น๐ ๐๐น๐ถ๐๐ฟยฎ ๐ฏ๐ถ๐ผ๐ฐ๐ผ๐ป๐ท๐๐ด๐ฎ๐๐ถ๐ผ๐ป for the delivery of nucleic acids via targeted polymeric and lipid nanoparticles (LNPs). Cristal Therapeutics and Curapath will both have the right to grant sublicenses in this exciting and rapidly expanding field.
๐๐ฟ. ๐ฃ๐ต๐ถ๐น๐ถ๐ฝ๐ฝ๐ฒ ๐๐น๐ฎ๐๐ฒ๐น, ๐๐๐ข ๐ผ๐ณ ๐๐๐ฟ๐ฎ๐ฝ๐ฎ๐๐ต, stated:
โActive targeting remains one of the greatest challenges in advanced drug delivery. By integrating Cristal Therapeuticsโ CliCrยฎ platform, Curapath strengthens its leadership in next-generation delivery systems, including targeting LNPs to extrahepatic tissues. This alliance enables us to offer innovators a scalable, precise, and stable bioconjugation solution, accelerating the development of safer, more effective targeted therapies.โ
๐๐ฟ. ๐ช๐ฒ๐ฟ๐ป๐ฒ๐ฟ ๐๐ฎ๐๐๐ฟ๐ฒ๐ฒ๐น๐, ๐๐๐ข ๐ผ๐ณ ๐๐ฟ๐ถ๐๐๐ฎ๐น ๐ง๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ฒ๐๐๐ถ๐ฐ๐, commented:
"We are very pleased to collaborate with Curapath, a strong and leading CDMO in the LNP field. This collaboration places CliCrยฎ in an excellent position to become the standard in bioconjugation to nanoparticles for nucleic acid drug delivery. It is another example for the broad applicability of the CliCrยฎ platform in therapeutic drug and diagnostic development."
The financial terms of the agreement were not disclosed.
๐๐ฏ๐ผ๐๐ ๐๐๐ฟ๐ฎ๐ฝ๐ฎ๐๐ต
Curapath is a science-driven CDMO specializing in the design, development, and GMP manufacturing of advanced drug delivery systems. Curapath supports biopharma companies from early R&D through to commercial production, enabling innovation across every stage. With a strong expertise in nanoencapsulation and non-viral gene delivery, Curapath offers polymer and lipid-based nanoparticles tailored for a wide variety of payloads. From excipient synthesis to drug product formulation, the flexible service model and proprietary technologies ensure a seamless path to the clinic. Committed to quality, innovation, and collaboration, Curapath helps bring next-generation therapies to market faster.
To know more about Curapath visit: https://curapath.com/
๐๐ฏ๐ผ๐๐ ๐๐ฟ๐ถ๐๐๐ฎ๐น ๐ง๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ฒ๐๐๐ถ๐ฐ๐ ๐ฎ๐ป๐ฑ ๐๐น๐ถ๐๐ฟยฎ
Cristal Therapeutics is a biotechnology company dedicated to the development of superior bioconjugates with improved therapeutic profiles for better treatment outcomes in patients. The companyโs proprietary CliCrยฎ copper-free click chemistry enables site-specific, rapid, and robust conjugation of a wide variety of biomolecules. Designed to operate under mild up to even extreme conditions, CliCrยฎ offers superior performance for applications in antibody-drug conjugates (ADCs), targeted delivery systems, diagnostics, and more. The conjugation is known for its unmatched precision, compatibility and ease of manufacturing up to and including under GMP. CliCrยฎ enhances therapeutic product quality by minimizing impurities and strengthening conjugate stability, resulting in extended circulation, higher efficacy, and improved patient safety.
To learn more about Cristal Therapeutics visit: https://cristaltherapeutics.com/
Curapath
Curapath
+34 963 76 90 80
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
